721-735 of 1197
Improving the Safety of Generic Pharmaceuticals
Clinician's RoundtableImproving the Safety of Generic Pharmaceuticals
Kathleen Jaeger, JD
Bruce Japsen
Kathleen Jaeger, JD
Bruce Japsen
Can A Consultant Help Your Greatest Practice Woes?
Clinician's RoundtableCan A Consultant Help Your Greatest Practice Woes?
Owen J. Dahl, MBA
Larry Kaskel, MD
The Impact of Heparin Contamination Going Forward
Clinician's RoundtableThe Impact of Heparin Contamination Going Forward
Jawed Fareed, PhD
Mark Nolan Hill, MD
The Global Implications of Heparin Contamination
Clinician's RoundtableThe Global Implications of Heparin Contamination
Jawed Fareed, PhD
Mark Nolan Hill, MD
Jawed Fareed, PhD
Mark Nolan Hill, MD
- advertisement
Recent Concerns About Heparin Contamination
Clinician's RoundtableRecent Concerns About Heparin Contamination
Jawed Fareed, PhD
Mark Nolan Hill, MD
To Admit or Observe: What Would CMS Say?
Clinician's RoundtableTo Admit or Observe: What Would CMS Say?
Robert Wagner, MD
Bill Rutenberg, MD
Sure Decision Clinical Compliance Program
Clinician's RoundtableSure Decision Clinical Compliance Program
Robert Wagner, MD
Bill Rutenberg, MD
Metformin For Prevention of Type II Diabetes
Clinician's RoundtableMetformin For Prevention of Type II Diabetes
Shelley Salpeter, MD
Lee Freedman, MD
Broader Considerations for NOTES Procedures
Clinician's RoundtableBroader Considerations for NOTES Procedures
Nathaniel Soper, MD
Mark Nolan Hill, MD
Nathaniel Soper, MD
Mark Nolan Hill, MD
- advertisement
Patient Populations Targeted for NOTES Procedures
Clinician's RoundtablePatient Populations Targeted for NOTES Procedures
Nathaniel Soper, MD
Mark Nolan Hill, MD
Nathaniel Soper, MD
Mark Nolan Hill, MD
American College of Cardiology 2008 Conference
Clinician's RoundtableAmerican College of Cardiology 2008 Conference
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Paul Raeburn